Oops, you're using an old version of your browser so some of the features on this page may not be displaying properly.

MINIMAL Requirements: Google Chrome 24+Mozilla Firefox 20+Internet Explorer 11Opera 15–18Apple Safari 7SeaMonkey 2.15-2.23

Illumina - Detection of homologous recombination deficiency (HRD): Role of HRD testing and impact on patient management

The value of biomarker testing for homologous recombination deficiency in prostate cancer

Date

22 Oct 2023

Session

Illumina - Detection of homologous recombination deficiency (HRD): Role of HRD testing and impact on patient management

Topics

Molecular Oncology;  Targeted Therapy;  Cancer Diagnostics

Tumour Site

Ovarian Cancer;  Prostate Cancer

Presenters

David Olmos

Authors

D. Olmos

Author affiliations

  • Medical Oncology, Hospital Universitario 12 de Octubre, 28041 - Madrid/ES

Resources

This content is available to ESMO members and event participants.

This site uses cookies. Some of these cookies are essential, while others help us improve your experience by providing insights into how the site is being used.

For more detailed information on the cookies we use, please check our Privacy Policy.

Customise settings
  • Necessary cookies enable core functionality. The website cannot function properly without these cookies, and you can only disable them by changing your browser preferences.